Letters

The PROGRESS trial three years later: HOPE trial may shed some light

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7479.1403-d (Published 09 December 2004) Cite this as: BMJ 2004;329:1403
  1. John Attia (John.Attia@newcastle.edu.au), associate professor, epidemiology,
  2. Catherine D'Este, associate professor biostatistics,
  3. Christopher R Levi, conjoint senior lecturer
  1. Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, NSW 2300, Australia
  2. Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, NSW 2300, Australia

    EDITOR—Wennberg and Zimmermann are correct in pointing out that it is simplistic, and potentially misleading, to interpret PROGRESS as indicating that patients with stroke benefit from the combination of perindopril and indapamide.1 In applying these results clinically, doctors need to know whether the benefit in stroke reduction is due mainly to indapamide or to some synergistic effect of the two. After all, given the prevalence …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe